Pamela Esposito, Director at Kymera Therapeutics, Inc. (KYMR), sold 5,000 shares at $49.04 ($245K) on 2025-06-03, disclosed to the SEC on 2025-06-03.
Scheduled sale ($245k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KYMR | SELL | 2026-01-20 | $707K | — | Filing → |
| KYMR | SELL | 2025-12-17 | $4.4M | — | Filing → |
| KYMR | SELL | 2024-12-02 | $123K | — | Filing → |